Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A benign or malignant tumor that arises from the testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the tumor or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, ten percent of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.
Biomarker and diagnostic research for testicular sex cord-stromal neoplasm has been reported in the published literature.
1 clinical trial registered. Interventions under study include procedural interventions and biologic therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
80 publications have been identified in PubMed for testicular sex cord-stromal neoplasm. Research spans Case Report / Case Series (46%), Review / Meta-Analysis (18%), and Basic Science / Preclinical (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 37 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:38 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 14 | 18% |
Laboratory research | 11 | 14% |
Testing and diagnosis research | 8 | 10% |
Disease patterns and progression | 6 | 8% |
Clinical study results | 2 | 3% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Guo B (2026). [PMID: 41917860](https://pubmed.ncbi.nlm.nih.gov/41917860/). *BMC Cancer*. [Epidemiology / Natural History]
Shiobara K (2026). [PMID: 42062885](https://pubmed.ncbi.nlm.nih.gov/42062885/). *Hinyokika Kiyo*. [Case Report / Case Series]
Okiro P (2026). [PMID: 41617645](https://pubmed.ncbi.nlm.nih.gov/41617645/). *Pediatr Dev Pathol*. [Case Report / Case Series]
Aljofan A (2026). [PMID: 41868008](https://pubmed.ncbi.nlm.nih.gov/41868008/). *Urol Case Rep*. [Case Report / Case Series]
Choiniere R (2026). [PMID: 41263775](https://pubmed.ncbi.nlm.nih.gov/41263775/). *Histopathology*. [Epidemiology / Natural History]
Lobo J (2026). [PMID: 41384702](https://pubmed.ncbi.nlm.nih.gov/41384702/). *Histopathology*. [Basic Science / Preclinical]
Nalluri BT (2026). [PMID: 41486225](https://pubmed.ncbi.nlm.nih.gov/41486225/). *Indian J Pediatr*. [Case Report / Case Series]
Lobo J (2026). [PMID: 41152570](https://pubmed.ncbi.nlm.nih.gov/41152570/). *J Pathol*. [Diagnostic / Biomarker]
Chen L (2026). [PMID: 42057139](https://pubmed.ncbi.nlm.nih.gov/42057139/). *Biomark Res*. [Gene Therapy / Novel Therapeutics]
Song J (2026). [PMID: 41676290](https://pubmed.ncbi.nlm.nih.gov/41676290/). *American journal of translational research*. [Case Report / Case Series]